SerpinD1 Proteins, Antibodies, cDNA Clones Research Reagents

SERPIND1 (Serpin Family D Member 1) is a protein coding gene located on human chromosome 22q11.21. SERPIND1 is also known as HC2, LS2, HCF2, HCII, HLS2, THPH10 and D22S673. The human SERPIND1 gene encodes a 57071 Da protein containing 499 amino acids. The SERPIND1 protein is restrictedly expressed toward liver. Among its related pathways are Formation of Fibrin Clot (Clotting Cascade) and Response to elevated platelet cytosolic Ca2+. SERPIND1 is related to heparin binding and endopeptidase inhibitor activity. SERPINB1 is an important paralog of SERPIND1 gene. SERPIND1 is associated with some diseases, including Heparin Cofactor Ii Deficiency and Thrombophilia.

SerpinD1 Protein (2)

    SerpinD1 Antibody (8)

      SerpinD1 cDNA Clone (26)


      SerpinD1 Lysate (2)

        SerpinD1 Background

        SerpinD1, also known as heparin cofactor II, is a member of Serpin superfamily of the serine proteinase inhibitors. HCII is a glycoprotein in human plasma that inhibits thrombin and chymotrypsin, and the rate of inhibition of thrombin is rapidly increased by Dermatan sulfate (DS), heparin (H) and glycosaminoglycans(GAG). The stimulatory effect of glycosaminoglycans on the inhibition is mediated, in part, by the N-terminal acidic domain of HCII. Interestingly, a C-terminal His-tagged recombinant HCII exhibits enhanced activity of thrombin inhibition. It has been suggested that HCII plays an unique and important role in vascular homeostasis, and accordingly mutations in this gene or congenital HCII deficiency is potentially associated with thrombosis. HCII specifically inhibits thrombin action at the site of vascular wall injury and HCII-thrombin complexes have been detected in human plasma. HCII protects against thrombin-induced vascular remodeling in both humans and mice and HCII is a predictive biomarker and therapeutic target for atherosclerosis. SerpinD1 also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.

        SerpinD1 References

        • Rau JC, et al. (2009) Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Exp Mol Pathol. 87(3): 178-83.
        • Aihara K, et al. (2009) Heparin cofactor II as a novel vascular protective factor against atherosclerosis. J Atheroscler Thromb. 16(5): 523-31.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.